A Phase 2 interventional study of vadadustat and epoetin alfa in Anemia and Dialysis-Dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics. Terminated at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.
Among the 27 studies testing vadadustat in Anemia, this one is the 24th largest by enrollment, is one of 3 that started in 2017, is one of 8 in phase 2, and was the 14th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:
Mackay Memorial Hospital
Ages 18+
vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2017.
This study's enrollment of 2 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 60 across the 27 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 27 have an industry lead sponsor. The 4 most frequent:
Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.
23 studies in Anemia by Akebia Therapeutics: none open now, none under way, none of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 23 studies in Anemia by Akebia Therapeutics, this one is the 20th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 2, and was the 16th registered.
Akebia Therapeutics’s Anemia studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing vadadustat in Anemia, from their registry updates:
Among Akebia Therapeutics’s 23 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, randomized, open-label study to evaluate vadadustat versus epoetin alfa for the treatment of anemia in subjects with Dialysis-dependent Chronic Kidney Disease (DD-CKD) who are hyporesponsive to erythropoiesis stimulating agents (ESAs.)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vadadustat daily oral dose, adjustable based on Hb level
Drug: vadadustat
Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study
Drug: epoetin alfa
vadadustat
Also known as: AKB-6548
epoetin alfa
Change From Baseline in Hemoglobin (Hb) Over Time During the Treatment Period
Time frame: Baseline; up to 20 weeks
Number of Participants Demonstrating Incremental Increases in Hb From Baseline Over Time During the Treatment Period
Time frame: Baseline; up to 20 weeks
Number of Participants With Hb Values Within the Target Range of 10.0-11.0 Grams Per Deciliter (g/dL) During the Treatment Period
Time frame: Baseline; up to 20 weeks
Number of Participants Receiving Epoetin Alfa Rescue
Time frame: up to 20 weeks
Number of Participants Receiving Red Blood Cell Transfusion
Time frame: up to 20 weeks
Number of Participants With Specified Levels of Various Biomarkers, Including C-reactive Protein, Hepcidin, and Vascular Endothelial Growth Factor
Time frame: up to 20 weeks
Mean Weekly Dose of Intravenous Elemental Iron Administered
Time frame: up to 20 weeks
Number of Participants Maintaining Iron Sufficiency (Defined as Ferritin ≥100 Nanograms Per Milliliter and Transferrin Saturation ≥20%)
Time frame: up to 20 weeks
Number of Participants Utilizing Resources
Time frame: up to 20 weeks
Number of Participants With Treatment-emergent Adverse Events
Treatment-emergent adverse events were collected in all participants enrolled in the study.
Time frame: up to 24 weeks
| Milestone | Vadadustat | Epoetin Alfa |
|---|---|---|
| Started | 0 | 2 |
| Completed | 0 | 2 |
| Not completed | 0 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Treatment-emergent adverse events were collected in all participants enrolled in the study.
| Participants | Vadadustat | Epoetin Alfa |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events | 0 | 0 |
Collected over up to Week 24. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vadadustat | — | — | — |
| Epoetin Alfa | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
All subjects enrolled in the trial.
| Age, Categorical(Participants) | Vadadustat | Epoetin Alfa | Total |
|---|---|---|---|
| <=18 years | — | 0 | 0 |
| Between 18 and 65 years | — | 1 | 1 |
| >=65 years | — | 1 | 1 |
| Sex: Female, Male(Participants) | Vadadustat | Epoetin Alfa | Total |
|---|---|---|---|
| Female | — | NA | NA |
| Male | — | NA | NA |
| Race (NIH/OMB)(Participants) | Vadadustat | Epoetin Alfa | Total |
|---|---|---|---|
| American Indian or Alaska Native | — | NA | NA |
| Asian | — | NA | NA |
| Native Hawaiian or Other Pacific Islander | — | NA | NA |
| Black or African American | — | NA | NA |
| White | — | NA | NA |
| More than one race | — | NA | NA |
| Unknown or Not Reported | — | NA | NA |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2017 to primary completion in Mar 2018, 10 months.
Results were first posted in Feb 2021, 2 years 11 months after primary completion. A results delay was requested in Sep 2018.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat